<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2017.72010</article-id><article-id pub-id-type="publisher-id">ACM-20931</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20170200000_31779473.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  骨髓增殖性肿瘤症状管理现状
  The Symptom Management of Myeloproliferative Neoplasms
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>李</surname><given-names>晓婧</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>李</surname><given-names>冬云</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>李</surname><given-names>潇</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>钱</surname><given-names>树树</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>北京中医药大学东直门医院，北京</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>04</day><month>05</month><year>2017</year></pub-date><volume>07</volume><issue>02</issue><fpage>59</fpage><lpage>65</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    骨髓增殖性肿瘤(MPN)是来源于克隆性造血干细胞的恶性肿瘤，包括真性红细胞增多症(PV)、原发性血小板增多症(ET)和骨髓纤维化(MF)。MPN患者存在疲劳、头痛、恶心、盗汗、瘙痒等不适症状，严重降低患者生活质量。近年来，研究重点转向对患者自我感知不适症状了解及控制上，本文介绍了MPN症状负荷及相关症状管理工具，突出中医药治疗MPN优势。
    Myeloproliferative neoplasms (MPN) are clonal hematopoietic stem cell-derived malignancies that include polycythemia vera (PV), essential thrombocythemia (ET) and myelofibrosis (MF). Symptoms experienced by MPN patients are fatigue, headache, nausea, night sweats, itching and so on, and these symptoms seriously reduce the quality of life, which in the group of this disease. In recent years, researchers pay attention to the self perceived symptom of MPN patients, and focus on the understanding and management towards these symptoms. This paper introduces the symptom burden of MPN and Symptom Assessment Tools, and emphasises on the advantage of Chinese medicine in the treatment of MPN. 
  
 
</p></abstract><kwd-group><kwd>骨髓增殖性肿瘤，症状管理，治疗，中医药, Myeloproliferative Neoplasms</kwd><kwd> Symptom Management</kwd><kwd> Therapy</kwd><kwd> Chinese Medicine and Pharmacy</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>骨髓增殖性肿瘤症状管理现状<sup> </sup></title><p>李晓婧，李冬云，李潇，钱树树</p><p>北京中医药大学东直门医院，北京</p><p>收稿日期：2017年5月17日；录用日期：2017年6月9日；发布日期：2017年6月12日</p><disp-formula id="hanspub.20931-formula47"><graphic xlink:href="http://html.hanspub.org/file/4-1570313x5_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s2"><title>摘 要</title><p>骨髓增殖性肿瘤(MPN)是来源于克隆性造血干细胞的恶性肿瘤，包括真性红细胞增多症(PV)、原发性血小板增多症(ET)和骨髓纤维化(MF)。MPN患者存在疲劳、头痛、恶心、盗汗、瘙痒等不适症状，严重降低患者生活质量。近年来，研究重点转向对患者自我感知不适症状了解及控制上，本文介绍了MPN症状负荷及相关症状管理工具，突出中医药治疗MPN优势。</p><p>关键词 :骨髓增殖性肿瘤，症状管理，治疗，中医药</p><disp-formula id="hanspub.20931-formula48"><graphic xlink:href="http://html.hanspub.org/file/4-1570313x6_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2017 by authors and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="http://image.hanspub.org:8080\Html/htmlimages\1-2890033x\e70a10f1-7c93-45ea-9603-062237856e4b.png" /><img src="http://image.hanspub.org:8080\Html\htmlimages\1-2890033x\e898c85e-ffc4-45c9-b817-14224a4d6960.png" /></p></sec><sec id="s3"><title>1. 引言</title><p>骨髓增殖性肿瘤(myeloproliferative neoplasms, MPNs)是来源于克隆性造血干细胞的恶性肿瘤，以骨髓一系或多系过度增殖为特征，其中BCR-ABL基因阴性疾病包括真性红细胞增多症(PV)、原发性血小板增多症(ET)和原发性骨髓纤维化(PMF)。骨髓增殖性疾病概念的提出是在1951年，Dameshek W [<xref ref-type="bibr" rid="hanspub.20931-ref1">1</xref>] 指出该病的特点是在骨髓中过度增殖的前体细胞及过度的产生成熟的血细胞。2005年Kenneth等 [<xref ref-type="bibr" rid="hanspub.20931-ref2">2</xref>] 发现JAK2V617F基因突变和激活的酪氨酸激酶在MPN发病中起重要作用，从此揭开了骨髓增殖性疾病在分子遗传学领域研究热潮。随后陆续发现了CALR、MPL、TET2等 [<xref ref-type="bibr" rid="hanspub.20931-ref3">3</xref>] 基因突变，并且发现CALR基因与预后有一定相关性 [<xref ref-type="bibr" rid="hanspub.20931-ref4">4</xref>] 。2008年，WHO [<xref ref-type="bibr" rid="hanspub.20931-ref5">5</xref>] 将骨髓增殖性疾病更名为骨髓增殖性肿瘤，突出其恶性特点。随着检查手段先进化及人群体检率增多，骨髓增殖性肿瘤的检出率增高，发病倾向于年轻化。来自韩国的一项流行病学调查 [<xref ref-type="bibr" rid="hanspub.20931-ref6">6</xref>] 发现，每年的发病率ET为2.0~3.0/10万，PV为1.0~1.5/10万，PMF为0.3~0.5/10万。尽管骨髓增殖性肿瘤为一种相对惰性的疾病，ET需要20~30 [<xref ref-type="bibr" rid="hanspub.20931-ref7">7</xref>] 年的时间转化为骨髓纤维化或白血病，但疾病带来的血栓、出血风险及身体不适症状仍给患者造成极大困扰，使患者生活质量降低。</p></sec><sec id="s4"><title>2. MPN患者症状异质性</title><p>MPN具有显著的症状异质性和临床表现多样性 [<xref ref-type="bibr" rid="hanspub.20931-ref8">8</xref>] ，不同的患者其表现的症状也有所不同，研究MPN患者症状负担，并且通过研究来改善其症状负担在提高患者生活质量方面具有重大意义 [<xref ref-type="bibr" rid="hanspub.20931-ref9">9</xref>] 。头痛是原发性血小板增多症常见的症状之一，与此同时，疲劳 [<xref ref-type="bibr" rid="hanspub.20931-ref10">10</xref>] 是MPN普遍存在的主要不适症状，有研究发现 [<xref ref-type="bibr" rid="hanspub.20931-ref11">11</xref>] ，不良的生活方式、抗精神类疾病药物及止痛药物的使用与MPN患者疲劳症状有相关性。而包括腹痛、腹胀、脾肿大在内的腹部不适以及其引起的厌食、恶心、早饱等不适症状也时时困扰着MPN患者正常生活。在PV患者中，水源性瘙痒症 [<xref ref-type="bibr" rid="hanspub.20931-ref12">12</xref>] 是一项典型症状，德国对PV患者进行的调查 [<xref ref-type="bibr" rid="hanspub.20931-ref13">13</xref>] 显示，441例患者中有301例患者存在水源性瘙痒，尽管抗组胺药及细胞减灭术能改善一部分病人症状，但仍需开辟新的治疗途径改善症状。MPN患者还存在与白细胞介素、干扰素、肿瘤坏死因子等相关的发热、盗汗症状。全血细胞减少在MF中常见，由此导致的严重疲劳、感染及出血，严重影响患者生活质量，甚至危及生命。</p><p>最近有调查研究 [<xref ref-type="bibr" rid="hanspub.20931-ref14">14</xref>] 显示，症状负荷带来的痛苦和焦虑普遍存在于MPN患者中，因此除了管理患者相关症状以外，还需要进一步的关心患者的心理状况，及时疏导。MPN的症状异质性决定了其病情危险程度、疗效和预后评价的不统一性，增加了疾病研究及治疗难度，亟需寻求统一的症状评价标准。</p></sec><sec id="s5"><title>3. MPN症状评估量表</title><p>2009年，Mesa等 [<xref ref-type="bibr" rid="hanspub.20931-ref15">15</xref>] 验证了MF症状评估量表(MF-SAF)的可行性，该量表包括了简易疲劳量表及MF特有症状在内的20项条目。随后在该量表基础上增加了包括头痛、头晕、感觉异常、失眠、抑郁、性功能下降等PV及ET存在的特殊症状条目，应用于BCR-ABL阴性MPN中，命名MPN-SAF。2011年Scherber等 [<xref ref-type="bibr" rid="hanspub.20931-ref8">8</xref>] 应用MPN-SAF对402例患者症状负荷进行调查研究，验证了该量表在临床试验中应用可靠性。随后，在临床实践评价中建议 [<xref ref-type="bibr" rid="hanspub.20931-ref16">16</xref>] 将MPN-SAF修改为简短版本，专注于最具代表性的MPN症状，MPN-SAF-TSS应运而生。该量表包含了最大疲劳、早饱、腹部不适、不活跃、社交问题、盗汗、瘙痒、骨痛、发热及体重减轻十项积分条目，量表简洁有效，能有效评估MPN患者异质性症状，并且有调查研究显示 [<xref ref-type="bibr" rid="hanspub.20931-ref17">17</xref>] ，PMF总症状负荷在MPN中得分最高，MPN-SAF-TSS能作为治疗研究评价指标应用于临床实践中。综上所述，MPN相关症状负荷量表的产生及应用为评估患者治疗效果及临床试验研究提供了方便。</p><p>总之，研究MPN症状负荷并寻求相关治疗方案，改变以往仅通过实验室指标来判断病情及疗效的观念是目前趋势。最近的研究结果 [<xref ref-type="bibr" rid="hanspub.20931-ref18">18</xref>] 也证实了将MPN症状负荷作为治疗评估手段及疗效指标具有里程碑式意义。</p></sec><sec id="s6"><title>4. MPN预后评分与危险分层</title><p>MPN中，中位生存期短、疾病恶性程度大的PMF症状负荷更重，严重影响疾病预后，MPN危险度分层对指导治疗及疾病预后有重要意义。既往研究 [<xref ref-type="bibr" rid="hanspub.20931-ref19">19</xref>] 发现，年龄在65岁以上、血红蛋白水平 &lt; 100 g/L、白细胞计数 &gt; 25 &#215; 10<sup>9</sup>/L、外周血原始细胞 ≥ 1%、全身症状出现等与PMF患者不良预后密切相关，称为IPSS评分系统。但该评分系统只适用于患者第一次诊断疾病时应用，无法反映时间变化对生存期的影响。Passamonti等 [<xref ref-type="bibr" rid="hanspub.20931-ref20">20</xref>] 提出MF国际动态预后评分系统(DIPSS)在临床应用的重要性，DIPSS可以在确诊后任意时间评分使用，对于治疗过程中根据疾病风险临时制定临床决策有指导作用。在DIPSS中，增加贫血在评分系统中的权重，将MF分为低危(0分)、中危-1 (1~2分)、中危-2 (3~4分)、高危(5~6分)，并且依次对应的中位生存期为未达到、14.2年、4年及1.5年。随后，因染色体异常核型、需要红细胞输注和血小板计数 &lt; 100 &#215; 10<sup>9</sup>/L与MF预后相关，增加以上三项评分条目，修改为DIPSS-plus [<xref ref-type="bibr" rid="hanspub.20931-ref21">21</xref>] 。ET及PV的预后评价，分别为IPSET及Tefferi评分系统。IPSET [<xref ref-type="bibr" rid="hanspub.20931-ref22">22</xref>] 评分可以有效评估ET患者的预后生存期及血栓发生风险，该系统包括年龄 ≥ 60岁、白细胞计数 ≥ 11 &#215; 10<sup>9</sup>/L、血栓形成史。Tefferi [<xref ref-type="bibr" rid="hanspub.20931-ref23">23</xref>] 系统将年龄、染色体异常及白细胞计数 ≥ 15 &#215; 10<sup>9</sup>/L作为PV转化为急性白血病的危险因素。</p><p>2014年，Holly等 [<xref ref-type="bibr" rid="hanspub.20931-ref24">24</xref>] 通过对1470例MPN患者进行回顾性研究再次细化了ET、PV、PMF不同危险分层的相关症状评分及预后结果，发现在低中风险患者中依然可以观察到明显的症状负担，识别这类患者群会影响到治疗方案、治疗时机及疗效目标选择，也强调了连续性症状负荷评估的重要作用。</p><p>近年来的研究 [<xref ref-type="bibr" rid="hanspub.20931-ref18">18</xref>] [<xref ref-type="bibr" rid="hanspub.20931-ref25">25</xref>] [<xref ref-type="bibr" rid="hanspub.20931-ref26">26</xref>] 偏重于分析评估MPN相关症状及对生活质量影响，Ruben A等 [<xref ref-type="bibr" rid="hanspub.20931-ref27">27</xref>] 首次探索了MPN症状评估在医生报告与患者报告之间的不同，强调医生应在治疗过程中更多的从患者角度出发理解MPN相关症状，加强医患沟通可能会改善患者预后及整体治疗满意度。另外，曾有文献支持 [<xref ref-type="bibr" rid="hanspub.20931-ref28">28</xref>] 性别可以潜在的影响基因表达及症状负担，一项来自MPN QOL IWG的研究 [<xref ref-type="bibr" rid="hanspub.20931-ref29">29</xref>] 证明，性别与MPN疾病特点及症状负担有一定联系，女性更易患ET、有腹痛症状的人数更多、在激素替代治疗中有更高的血栓风险，尽管女性对不适症状的描述更加频繁，但男性与女性在生活质量下降方面无明显差异，提出进一步考虑性别差异设计治疗方案。总之，不再把血象指标作为判断MPN疾病轻重的唯一标准，更加重视患者的自身主观感受，而如何减轻MPN的症状负荷，提高患者的生活质量成为当前临床亟需解决的重要问题。</p></sec><sec id="s7"><title>5. MPN症状相关治疗</title><p>骨髓增殖性肿瘤更名后，突出了其恶性特点及难治性。除造血干细胞移植外，骨髓增殖性肿瘤尚没有完全治愈方法。但造血干细胞移植后骨髓抑制 [<xref ref-type="bibr" rid="hanspub.20931-ref30">30</xref>] 所带来的感染、出血等并发症以及移植物抗宿主病 [<xref ref-type="bibr" rid="hanspub.20931-ref31">31</xref>] 等也给患者带来极大的痛苦，生活质量下降 [<xref ref-type="bibr" rid="hanspub.20931-ref32">32</xref>] 。目前PV、ET治疗是以减少血栓形成风险为目标的传统治疗方法，包括放血、低剂量阿司匹林及肿瘤细胞减灭治疗(羟基脲及干扰素)；而对于PMF来说，治疗主要集中于对贫血、出血等并发症的对症处理。无论哪一种方法，都无法解决患者不适症状导致生活质量下降的问题，并且带来许多药物副反应，患者常因不耐受而停药。随着MPN分子生物学研究深入，各类靶向药相继问世。2011年美国FDA批准芦可替尼(Ruxolitinib)作为MF用药上市，研究 [<xref ref-type="bibr" rid="hanspub.20931-ref33">33</xref>] [<xref ref-type="bibr" rid="hanspub.20931-ref34">34</xref>] 已经证实了芦可替尼能够有效减小MF患者脾大并改善全身症状；后于2014年批准用于羟基脲不耐受或耐药的PV患者。芦可替尼治疗PV的有效性也得到证实 [<xref ref-type="bibr" rid="hanspub.20931-ref35">35</xref>] 。最近一项来自台湾的研究 [<xref ref-type="bibr" rid="hanspub.20931-ref36">36</xref>] 第一次证实了芦可替尼在亚洲人群应用的有效性及安全性，由于尚缺乏其安全性的大数据研究，以及高昂的治疗费用，目前在国内较少应用于临床。</p></sec><sec id="s8"><title>6. 中医药在MPN症状管理优势</title><p>目前MPN研究重点放在了减轻患者不适症状方面，把疲劳、瘙痒、性功能障碍、抑郁等对患者生活质量影响极大的症状放在更高重视地位 [<xref ref-type="bibr" rid="hanspub.20931-ref25">25</xref>] [<xref ref-type="bibr" rid="hanspub.20931-ref27">27</xref>] 。这一改变恰恰能够突显中医药治疗MPN的优势。而中医药在控制MPN的症状上也显示良好的治疗前景，因为不同的患者虽然患同一疾病，但其症状的表现却有不同，表现症状的数量不同，轻重不一，中医治疗通过综合望闻问切四诊，辨证论治，能针对每一位MPN患者提供个体化治疗，从而提高MPN患者的生活质量。同时有研究 [<xref ref-type="bibr" rid="hanspub.20931-ref37">37</xref>] [<xref ref-type="bibr" rid="hanspub.20931-ref38">38</xref>] 证实，活血化瘀法、凉血解毒法等中医治法在MPN治疗中能发挥良效，在减轻患者不适症状方面起到巨大作用，且经济方便。</p><p>骨髓增殖性肿瘤是现代医学名词，祖国医学原本没有此病名，但确有对其临床症状的具体描述，可归属于中医学“虚劳”、“血证”、“血瘀”、“癥积”、“热毒”等 [<xref ref-type="bibr" rid="hanspub.20931-ref39">39</xref>] 范畴。其病机特点总属“血瘀 [<xref ref-type="bibr" rid="hanspub.20931-ref40">40</xref>] ”，中医治疗讲究辨证论治，强调个体化，在临床遣方用药方面各方医家又各有特色。刘宝文 [<xref ref-type="bibr" rid="hanspub.20931-ref41">41</xref>] 认为气滞、血瘀、热蕴为MPN主要病机，在此基础上根据多年临床经验将MPN分为三个证型：肝火上炎兼血瘀；肝肾阴虚兼血瘀；气血亏虚兼血瘀。李达 [<xref ref-type="bibr" rid="hanspub.20931-ref42">42</xref>] 认为ET多数因虚或因实致瘀，并且与肝肾两脏相关。杨文华 [<xref ref-type="bibr" rid="hanspub.20931-ref43">43</xref>] 认为PV病因主要为嗜酒与恣食肥甘、情志内伤、外感邪毒等，其病机主要为血瘀。王梦亚 [<xref ref-type="bibr" rid="hanspub.20931-ref44">44</xref>] 认为MF的病机主要归于脾肾亏虚不化气血，瘀血内停阻滞气机，瘀血贯穿整个疾病发展始终。在中医药治疗中，认清患者的“证”是遣方用药的关键。中医通过四诊合参，针对MPN辨证论治包括活血化瘀法、清肝泄火法、清热凉血法、清热解毒法、补气活血法等。在中医辨证的过程中，每个医生对病人病情资料收集的不同、关注点侧重不同，都导致辨证结果不同。根据这种现状，已有医生 [<xref ref-type="bibr" rid="hanspub.20931-ref45">45</xref>] 通过数据处理技术探讨MPN的中医辨证及用药规律。通过对骨髓增殖性肿瘤证候分布特点研究，发现证候规律，对指导临床辨证及疾病病因、病机研究有指导作用。</p><p>骨髓增殖性肿瘤的治疗仍存在许多问题及挑战，其关注点向症状负荷的转变，突出对患者自我感知不适的重视程度，更加关注患者生活质量，这一特点能够使中医药治疗优势得以发挥，造福MPN患者。但目前中医药治疗MPN，临床上遣方用药多通过医家自身用药经验所得，尚缺乏统一认识，也缺乏对其证候、证素分布规律的大样本量的高级别的循证医学的研究。因此针对MPN的中医病机认识及用药规律尚需要进一步研究，可以通过骨髓增殖性肿瘤临床证素观察的方法进行归纳。临床证素研究可以辨别各项临床证侯之主次轻重、兼夹错杂，继而发现证素规律及由此反映出的病变本质差异，对指导临床辨证及疾病病因、病机研究有指导作用。因此，进行骨髓增殖性肿瘤的临床证候、证素分布规律研究具有一定的现实意义。归纳总结其证候及证素分布规律，明确骨髓增殖性肿瘤的中医证素，为该病证素辨证提供客观化依据。</p></sec><sec id="s9"><title>文章引用</title><p>李晓婧,李冬云,李 潇,钱树树. 骨髓增殖性肿瘤症状管理现状The Symptom Management of Myeloproliferative Neoplasms[J]. 临床医学进展, 2017, 07(02): 59-65. http://dx.doi.org/10.12677/ACM.2017.72010</p></sec><sec id="s10"><title>参考文献 (References)</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.20931-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Dameshek, W. (1951) Some Speculations on the Myeloproliferative Syndromes. Blood, 6, 372-375.</mixed-citation></ref><ref id="hanspub.20931-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Kaushansky, K. (2005) On the Molecular Origins of the Chronic Myeloproliferative Disorders: It All Makes Sense. Blood, 105, 4187-4190. &lt;br&gt;https://doi.org/10.1182/blood-2005-03-1287</mixed-citation></ref><ref id="hanspub.20931-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Tefferi, A. (2010) Novel Mutations and Their Functional and Clinical Relevance in Myeloproliferative Neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia, 24, 1128-1138. &lt;br&gt;https://doi.org/10.1038/leu.2010.69</mixed-citation></ref><ref id="hanspub.20931-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Kim, S.Y., Im, K., Park, S.N., et al. (2015) CALR, JAK2, and MPL Mutation Profiles in Patients with Four Different Subtypes of Myeloproliferative Neoplasms Primary Myelofibrosis, Essential Thrombocythemia, Pol-ycythemia Vera, and Myeloproliferative Neoplasm, Unclassifiable. American Journal of Clinical Pathology, 143, 635-644.  
&lt;br&gt;https://doi.org/10.1309/AJCPUAAC16LIWZMM</mixed-citation></ref><ref id="hanspub.20931-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Tefferi, A., Thiele, J., Orazi, A., et al. (2007) Proposals and Rationale for Revision of the World Health Organization Diagnostic Criteria for Polycythemia Vera, Essential Thrombocythemia, and Primary Myelofibrosis: Recommendations from an Ad Hoc International Expert Panel. Blood, 110, 1092-1097.  
&lt;br&gt;https://doi.org/10.1182/blood-2007-04-083501</mixed-citation></ref><ref id="hanspub.20931-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Byun, J.M., Kim,Y.J., Youk, T. et al. (2016) Real World Epidemiology of Myeloproliferative Neoplasms: A Population Based Study in Korea 2004-2013. Annals of Hematology, 96, 373-381. &lt;br&gt;https://doi.org/10.1007/s00277-016-2902-9</mixed-citation></ref><ref id="hanspub.20931-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Wolanskyj, A.P., Schwager, S.M., McClure, R.F., Larson, D.R. and Tefferi, A. (2006) Essential Thrombocythemia beyond the First Decade: Life Expectancy, Long-Term Complication Rates, and Prognostic Factors. Mayo Clinic Proceedings, 81, 159-166. &lt;br&gt;https://doi.org/10.4065/81.2.159</mixed-citation></ref><ref id="hanspub.20931-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Scherber, R.M., Geyer, H.L. and Mesa, R.A. (2014) Quality of Life in MPN Comes of Age as a Therapeutic Target. Current Hematologic Malignancy Reports, 9, 324-330. &lt;br&gt;https://doi.org/10.1007/s11899-014-0239-9</mixed-citation></ref><ref id="hanspub.20931-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Scherber, R., Dueck, A.C., Johansson, P., et al. (2011) The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): International Prospective Validation and Reliability Trial in 402 Patients. Blood, 118, 401-408.  
&lt;br&gt;https://doi.org/10.1182/blood-2011-01-328955</mixed-citation></ref><ref id="hanspub.20931-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Mesa, R.A., Niblack, J., Wadleigh, M., et al. (2007) The Burden of Fatigue and Quality of Life in Myeloproliferative Disorders (MPDs): An International Internet-Based Survey of 1179 MPD Patients. Cancer, 109, 68-76.  
&lt;br&gt;https://doi.org/10.1002/cncr.22365</mixed-citation></ref><ref id="hanspub.20931-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Scherber, R.M., Kosiorek, H.E., Senyak, Z., et al. (2016) Comprehensively Under-standing Fatigue in Patients with Myeloproliferative Neoplasms. Cancer, 122, 477-485. &lt;br&gt;https://doi.org/10.1002/cncr.29753</mixed-citation></ref><ref id="hanspub.20931-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Saini, K.S., Patnaik, M.M. and Tefferi, A. (2010) Polycythemiavera-Associated Pruritus and Its Management. European Journal of Clinical Investigation, 40, 828-834. &lt;br&gt;https://doi.org/10.1111/j.1365-2362.2010.02334.x</mixed-citation></ref><ref id="hanspub.20931-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Siegel, F.P., Tauscher, J. and Petrides, P.E. (2013) Aquagenic pruritus in Polycythemia vera: Characteristics and Influence on Quality of Life in 441 Patients. American Journal of Hematology, 88, 665-669.  
&lt;br&gt;https://doi.org/10.1002/ajh.23474</mixed-citation></ref><ref id="hanspub.20931-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Mc Fariand, D.C., Polizzi, H., Mascarenhas, J., et al. (2016) Psychological Symptoms among Patients with BCR- ABL-Negative Myeloproliferative Neoplasms. Journal of the National Comprehensive Cancer Network, 14, 1563- 1570.</mixed-citation></ref><ref id="hanspub.20931-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Mesa, R.A., Schwager, S., Radia, D., et al. (2009) The Myelofibrosis Symptom Assessment Form (MFSAF): An Evidence-Based Brief Inventory to Measure Quality of Life and Symptomatic Response to Treatment in Myelofibrosis. Leukemia Research, 33, 1199-1203.</mixed-citation></ref><ref id="hanspub.20931-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Emanuel, R.M., Dueck, A.C., Geyer, H.L., et al. (2012) Myeloproliferative Neoplasm (MPN) Symp-tom Assessment Form Total Symptom Score: Prospective International Assessment of an Abbreviated Symptom Burden Scoring Sys-tem among Patients with MPNs. Journal of Clinical Oncology, 30, 4098-4103.  
&lt;br&gt;https://doi.org/10.1200/JCO.2012.42.3863</mixed-citation></ref><ref id="hanspub.20931-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">徐俊卿, 徐泽锋, 王静雅, 等. 615例ph染色体/BCR-ABL融合基因阴性骨髓增殖性肿瘤患者的症状负荷评估[J]. 中华血液学杂志, 2016, 37(01): 26-29.</mixed-citation></ref><ref id="hanspub.20931-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Ruben, M., Carole, B., Maureen, T., et al. (2016) Myeloproliferative neoplasms (MPNs) Have a Significant Impact on Patients’ Overall Health and Productivity: the MPN Landmarksurvey. BMC Cancer, 16, 167.  
&lt;br&gt;https://doi.org/10.1186/s12885-016-2208-2</mixed-citation></ref><ref id="hanspub.20931-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Cervantes, F., Dupriez, B., Pereira, A., et al. (2009) New Prognostic Scoring System for Primary Myelofibrosis Based on a Study of the International Working Group for Myelofibrosis Research and Treatment. Blood, 113, 2895-2901.  
&lt;br&gt;https://doi.org/10.1182/blood-2008-07-170449</mixed-citation></ref><ref id="hanspub.20931-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Passamonti, F., Cervantes, F., Vannucchi, A.M., et al. (2010) A Dynamic Prognostic Model to Predict Survival in Primary Myelofibrosis: A Study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood, 115, 1703-1708. &lt;br&gt;https://doi.org/10.1182/blood-2009-09-245837</mixed-citation></ref><ref id="hanspub.20931-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Gangat, N., Caramazza, D., Vaidya, R., et al. (2011) DIPSS plus: A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates Prognostic Information Fromkaryotype, Platelet Count, and Transfusion Status. Journal of Clinical Oncology, 29, 392-397. &lt;br&gt;https://doi.org/10.1200/JCO.2010.32.2446</mixed-citation></ref><ref id="hanspub.20931-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Passamonti, F., Thiele, J., Girodon, F., et al. (2012) A Prognostic Model to Predict Survival in 867 World Health Organization-Defined Essential Thrombocy-Themia at Diagnosis: A Study by the International Working Group on Myelofibrosis Research and Treatment. Blood, 120, 1197-1201. &lt;br&gt;https://doi.org/10.1182/blood-2012-01-403279</mixed-citation></ref><ref id="hanspub.20931-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Tefferi, A., Rumi, E., Finazzi, G., et al. (2013) Survival and Prognosis among 1545 Patients with Contemporary Polycythemia Vera: An International Study. Leukemia, 27, 1874-1881. &lt;br&gt;https://doi.org/10.1038/leu.2013.163</mixed-citation></ref><ref id="hanspub.20931-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Geyer, H.L., Scherber, R.M., Dueck, A.C., et al. (2014) Distinct Clustering of Symptomatic Burden among Myeloproliferative Neoplasm Patients: Retrospective Assessment in 1470 Patients. Blood, 123, 3803-3810.  
&lt;br&gt;https://doi.org/10.1182/blood-2013-09-527903</mixed-citation></ref><ref id="hanspub.20931-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Anderson, L.A., James, G., Duncombe, A.S., et al. (2015) Myeloprolifera-tive Neoplasm Patient Symptom Burden and Quality of Life: Evidence of Significant Impairment Compared to Controls. American Journal of Hematology, 90, 864- 870. &lt;br&gt;https://doi.org/10.1002/ajh.24098</mixed-citation></ref><ref id="hanspub.20931-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Mesa, R.A., Scherber, R.M. and Geyer, H.L. (2015) Reducing Symptom Burden in Patients with Myeloproliferative Neoplasms in the Era of Janus Kinase Inhibitors. Leukemia &amp; Lymphoma, 56, 1989-1999.  
&lt;br&gt;https://doi.org/10.3109/10428194.2014.983098</mixed-citation></ref><ref id="hanspub.20931-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Ruben, A., Mesa, M.D., Carole, B., et al. (2017) Differences in Treatment Goals and Perception of Symptom Burden between Patients with Myeloproliferative Neoplasms (MPNs) and Hematolo-gists/Oncologists in the United States: Findings from the MPN Landmark Survey. Cancer, 123, 449-458. &lt;br&gt;https://doi.org/10.1002/cncr.30325</mixed-citation></ref><ref id="hanspub.20931-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Spivak, J.L., Considine, M., Williams, D.M., et al. (2014) Two Clinical Phenotypes in Polycythemia Vera. The New England Journal of Medicine, 371, 808-817. &lt;br&gt;https://doi.org/10.1056/NEJMoa1403141</mixed-citation></ref><ref id="hanspub.20931-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">Geyer, H.L., Kosiorek, H., Dueck, A.C., et al. (2017) Associations between Gender, Disease Features and Symptom Burden in Patients with Myeloproliferative Neoplasms: An Analysis by the MPN QOL International Working Group. Haematologica, 102, 85-93. &lt;br&gt;https://doi.org/10.3324/haematol.2016.149559</mixed-citation></ref><ref id="hanspub.20931-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">Frödin, U., Lotfi, K. and Fomichov, V. (2015) Frequent and Long-Term Follow-Up of Health-Related Quality of Life Following Allogeneic Haematopoietic Stem Cell Transplantation. European Journal of Cancer Care, 24, 898-910.  
&lt;br&gt;https://doi.org/10.1111/ecc.12350</mixed-citation></ref><ref id="hanspub.20931-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">Krupski, C. and Jagasia, M. (2015) Quality of Life in the Chronic GVHD Consortium Cohort: Lessons Learned and the Long Road Ahead. Current Hematologic Malignancy Reports, 10, 183-191.  
&lt;br&gt;https://doi.org/10.1007/s11899-015-0265-2</mixed-citation></ref><ref id="hanspub.20931-ref32"><label>32</label><mixed-citation publication-type="other" xlink:type="simple">Song, C.E. and So, H.S. (2015) Factors Influencing Changes in Quality of Life in Patients undergoing Hematopoietic Stem Cell Transplantation: A Longitudinal and Multilevel Analysis. Journal of Korean Academy of Nursing, 45, 694- 703. &lt;br&gt;https://doi.org/10.4040/jkan.2015.45.5.694</mixed-citation></ref><ref id="hanspub.20931-ref33"><label>33</label><mixed-citation publication-type="other" xlink:type="simple">Verstovsek, S., Mesa, R.A., Gotlib, J., et al. (2012) A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis. The New England Journal of Medicine, 366, 799-807. &lt;br&gt;https://doi.org/10.1056/NEJMoa1110557</mixed-citation></ref><ref id="hanspub.20931-ref34"><label>34</label><mixed-citation publication-type="other" xlink:type="simple">Harrison, C., Kiladjian, J.-J., Al-Ali, H.K., et al. (2012) JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis. The New England Journal of Medicine, 366, 787-798. &lt;br&gt;https://doi.org/10.1056/NEJMoa1110556</mixed-citation></ref><ref id="hanspub.20931-ref35"><label>35</label><mixed-citation publication-type="other" xlink:type="simple">Bryan, J.C. and Verstovsek, S. (2016) Overcoming Treatment Challenges in Myelofibrosis and Polycythemia Vera: The Role of Ruxolitinib. Cancer Chemotherapy and Pharmacology, 77, 1125-1142.  
&lt;br&gt;https://doi.org/10.1007/s00280-016-3012-z</mixed-citation></ref><ref id="hanspub.20931-ref36"><label>36</label><mixed-citation publication-type="other" xlink:type="simple">Chen, Y.-Y., Huang, C.-E., Lee, K.-D., et al. (2016) Clinical Efficacy and Safety of Ruxolitinib in the Management of Myelofibrosis: A Single Institution Experience in Taiwan. Hematology, 21, 3-9.  
&lt;br&gt;https://doi.org/10.1179/1607845415Y.0000000036</mixed-citation></ref><ref id="hanspub.20931-ref37"><label>37</label><mixed-citation publication-type="other" xlink:type="simple">李仕能. 凉血解毒, 活血理气方治疗原发性血小板增多症(血瘀证)的临床疗效观察[D]: [硕士学位论文]. 长沙: 湖南中医药大学, 2015.</mixed-citation></ref><ref id="hanspub.20931-ref38"><label>38</label><mixed-citation publication-type="other" xlink:type="simple">翟冰冰. 活血化瘀解毒法治疗原发性血小板增多症的临床观察[D]: [硕士学位论文]. 广州: 广州中医药大学, 2015.</mixed-citation></ref><ref id="hanspub.20931-ref39"><label>39</label><mixed-citation publication-type="other" xlink:type="simple">陈信义, 麻柔, 李冬云. 规范常见血液病中医病名建议[J]. 中国中西医结合杂志, 2009, 29(11): 1040-1041.</mixed-citation></ref><ref id="hanspub.20931-ref40"><label>40</label><mixed-citation publication-type="other" xlink:type="simple">赖宗浪, 史雯, 马薇, 黄晓. 李冬云运用理气活血法治疗骨髓增殖性肿瘤的临床经验[J]. 北京中医药, 2014, 33(4): 263-266.</mixed-citation></ref><ref id="hanspub.20931-ref41"><label>41</label><mixed-citation publication-type="other" xlink:type="simple">周己扬, 王嫱, 刘欣, 等. 基于数据挖掘的刘宝文教授治疗骨髓增殖性疾病用药特色分析[J]. 世界中医药, 2016, 11(3): 550-553.</mixed-citation></ref><ref id="hanspub.20931-ref42"><label>42</label><mixed-citation publication-type="other" xlink:type="simple">梁春灵. 李达以“血积”辨治原发性血小板增多症经验[J]. 中华中医药杂志, 2016, 31(1): 158-160.</mixed-citation></ref><ref id="hanspub.20931-ref43"><label>43</label><mixed-citation publication-type="other" xlink:type="simple">冯全管. 杨文华治疗真性红细胞增多症验案1则[J]. 湖南中医杂志, 2016, 32(9): 107-108.</mixed-citation></ref><ref id="hanspub.20931-ref44"><label>44</label><mixed-citation publication-type="other" xlink:type="simple">王梦亚. 原发性骨髓纤维化的中医药治疗探析[J]. 中医研究, 2016, 29(8): 9-11.</mixed-citation></ref><ref id="hanspub.20931-ref45"><label>45</label><mixed-citation publication-type="other" xlink:type="simple">李达. 运用数据处理技术探讨原发性血小板增多症的中医辨证和用药规律[J]. 医学研究与教育, 2015, 32(5): 29- 34.</mixed-citation></ref></ref-list></back></article>